Patients with highly expressing BCL-XL tumours had a non-significant, but strong trend towards inferior OS (11.8 versus 16.8 months) (HR 1.36, 95% CI 0.99–1.86, p = 0.057) but not high MCL-1 expression (13.5 versus 11.6 months) (HR 0.8, 95% CI 0.64–1.01, p = 0.064). The gene discussed is BCL2L1; the disease is neoplasm.